This is not the most recent version of the article. View current version (3 AUG 2014)

Intervention Protocol

You have free access to this content

Aspirin as adjunctive treatment for giant cell arteritis

  1. Susan P Mollan1,*,
  2. Michael Marrone2,
  3. Mike A Burdon1,
  4. Leonard A Levin3,4,
  5. Alastair K Denniston1,5

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010453


How to Cite

Mollan SP, Marrone M, Burdon MA, Levin LA, Denniston AK. Aspirin as adjunctive treatment for giant cell arteritis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010453. DOI: 10.1002/14651858.CD010453.

Author Information

  1. 1

    Queen Elizabeth Hospital, Ophthalmology Department, University Hospitals Birmingham NHS Trust, Birmingham, UK

  2. 2

    Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland, USA

  3. 3

    McGill University, Montreal, QC, Canada

  4. 4

    University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

  5. 5

    University of Birmingham, Birmingham and Midland Eye Centre, Academic Unit of Ophthalmology, Birmingham, UK

*Susan P Mollan, Ophthalmology Department, University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital, Birmingham, UK. soozmollan@doctors.org.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (03 AUG 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

  1. To perform a systematic review of best-available evidence regarding the use of low dose aspirin, as an adjunctive, in the treatment of giant cell arteritis (GCA).
  2. To investigate the efficacy of aspirin in reducing morbidity and mortality in GCA.
  3. To document the incidence of adverse effects related to aspirin use in GCA.